Bleeding complications during anticoagulant treatment in patients with cancer

Thrombosis Research

Volumn 133, Issue SUPPL. 2, 2014, Pages

  Kamphuisen, Pieter W ^a   Beyer Westendorf, Jan ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Anticoagulation; Bleeding; Cancer; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CANCER PATIENT; HIGH RISK PATIENT; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOEMBOLISM PROPHYLAXIS; BLOOD; CHEMICALLY INDUCED; COMPLICATION; NEOPLASM; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEMORRHAGE; HUMANS; NEOPLASMS; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

EID: 84901445907     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(14)50009-6     Document Type: Article

References (63)

1. B. Gagnon, I. Mancini, J. Pereira, and E. Bruera Palliative management of bleeding events in advanced cancer patients J Palliat Care 14 1998 50 54 (Pubitemid 128639913)
2. G.H. Lyman, L. Eckert, Y. Wang, H. Wang, and A. Cohen Venous Thromboembolism Risk in Patients With Cancer Receiving Chemotherapy: A Real-World Analysis Oncologist 18 2013 1321 1329
3. E. Prommer Management of bleeding in the terminally ill patient Hematology 10 2005 167 175 (Pubitemid 41801133)
4. C.A. Schiffer, K.C. Anderson, C.L. Bennett, S. Bernstein, L.S. Elting, and M. Goldsmith et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology J Clin Oncol 19 2001 1519 1538 (Pubitemid 32202560)
5. K.L. Burbury, J.F. Seymour, R. Dauer, and D.A. Westerman Under-recognition of platelet dysfunction in myelodysplastic syndromes: Are we only seeing the tip of the iceberg? Leuk Lymphoma 54 2013 11 13
6. S. Sallah, and J.Y. Wan Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine Thromb Haemost 86 2001 1119 1121 (Pubitemid 32975845)
7. A.B. Federici Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg? J Thromb Haemost 6 2008 565 568 (Pubitemid 351404922)
8. D.E. Peterson, and A. Cariello Mucosal damage: A major risk factor for severe complications after cytotoxic therapy Semin Oncol 3 Suppl 8 2004 35 44 (Pubitemid 38879407)
9. M. Darmon, F. Vincent, L. Camous, E. Canet, C. Bonmati, and T. Braun et al. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Reanimation Respiratoire et Onco-Hematologique Br J Haematol 162 2013 489 497
10. S. Sallah, J.Y. Wan, N.P. Nguyen, L.R. Hanrahan, and G. Sigounas Disseminated intravascular coagulation in solid tumors: clinical and pathologic study Thromb Haemost 86 2001 828 833 (Pubitemid 32834193)
11. M.K. Gould, D.A. Garcia, S.M. Wren, P.J. Karanicolas, J.I. Arcelus, and J.A. Heit et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl 2012 e227S e277S
12. G. Agnelli, G. Bolis, L. Capussotti, R.M. Scarpa, F. Tonelli, and E. Bonizzoni et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project Ann Surg 243 2006 89 95 (Pubitemid 43054059)
13. G. Srivastava, V. Rana, S. Wallace, S. Taylor, M. Debnam, and L. Feng et al. Risk of intracranial hemorrhage and cerebrovascular accidents in non-small cell lung cancer brain metastasis patients J Thorac Oncol 4 2009 333 337
14. A.M. Stalfelt, H. Brodin, S. Pettersson, and A. Eklof The final phase in acute myeloid leukaemia (AML). A study on bleeding, infection and pain Leuk Res 27 2003 481 488 (Pubitemid 36315778)
15. M. Pihusch Bleeding complications after hematopoietic stem cell transplantation Semin Hematol 41 1 Suppl 1 2004 93 100 (Pubitemid 38182724)
16. W.X. Qi, L.N. Tang, Y.J. Sun, A.N. He, F. Lin, and Z. Shen et al. Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: An up-to-date meta-analysis of 27 randomized controlled trials Ann Oncol 24 2013 2943 2952
17. G. Agnelli, and M. Verso Thromboprophylaxis during chemotherapy after advanced cancer Thromb Res 120 Suppl 2 2007 S128 S132
18. A.K. Kakkar, M.N. Levine, Z. Kadziola, N.R. Lemoine, V. Low, and H.K. Patel et al. Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malginancy Outcome Study (FAMOUS) J Clin Oncol 22 2004 1944 1948 (Pubitemid 41095187)
19. G. Agnelli, D.J. George, A.K. Kakkar, W. Fisher, M.R. Lassen, and P. Mismetti et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer N Engl J Med 366 2012 601 609
20. A. Maraveyas, J. Waters, R. Roy, D. Fyfe, D. Propper, and F. Lofts et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer Eur J Cancer 48 2012 1283 1292
21. H. Riess, U. Pelzer, A. Hilbig, J. Stieler, B. Opitz, and T. Scholten et al. Rationale and design of PROSPECT-CONKO 004: A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy) BMC Cancer 8 2008 361
22. J.R. Perry, J.A. Julian, N.J. Laperriere, W. Geerts, G. Agnelli, and L.R. Rogers et al. PRODIGE: A randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma J Thromb Haemost 8 2010 1959 1965
23. A. Palumbo, M. Cavo, S. Bringhen, E. Zamagni, A. Romano, and F. Patriarca et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial J Clin Oncol 29 2011 986 993
24. A. Larocca, F. Cavallo, S. Bringhen, F. Di Raimondo, A. Falanga, and A. Evangelista et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide Blood 119 2012 933 939 quiz 1093
25. F.F. Van Doormaal, M. Di Nisio, H.M. Otten, D.J. Richel, M. Prins, and H.R. Buller Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer J Clin Oncol 29 2011 2071 2076
26. C.P. Klerk, S.M. Smorenburg, H.M. Otten, A.W. Lensing, M.H. Prins, and F. Piovella et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy J Clin Oncol 23 2005 2130 2135 (Pubitemid 46218704)
27. K. Sideras, P.L. Schaefer, S.H. Okuno, J.A. Sloan, L. Kutteh, and T.R. Fitch et al. Low- molecular-weight heparin in patients with advanced cancer: A phase 3 clinical trial Mayo Clin Proc 81 2006 758 767 (Pubitemid 43839491)
28. M. Di Nisio, E. Porreca, N. Ferrante, H.M. Otten, F. Cuccurullo, and A.W. Rutjes Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy Cochrane Database Syst Rev 2 2012 CD008500
29. M. Phan, S. John, A.I. Casanegra, S. Rathbun, A. Mansfield, and J.A. Stoner et al. Primary venous thromboembolism prophylaxis in patients with solid tumors: A meta-analysis J Thromb Thrombolysis 2013 [Epub ahead of print]
30. G.H. Lyman, A.A. Khorana, A. Falanga, D. Clarke-Pearson, C. Flowers, and M. Jahanzeb et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer J Clin Oncol 25 2007 5490 5505 (Pubitemid 350232226)
31. S.R. Kahn, W. Lim, A.S. Dunn, M. Cushman, F. Dentali, and E.A. Akl et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2 Suppl 2012 e195S e226S
32. A.A. Khorana, C.W. Francis, E. Culakova, N.M. Kuderer, and G.H. Lyman Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients Cancer 110 2007 2339 2346 (Pubitemid 350100757)
33. R. Alikhan, A.T. Cohen, S. Combe, M.M. Samama, L. Desjardins, and A. Eldor et al. Prevention of venous thromboembolism in medical patients with enoxaparin: A subgroups analysis of the MEDENOX study Blood 14 2003 341 346 (Pubitemid 36688187)
34. H. Riess, S. Haas, U. Tebbe, H.E. Gerlach, C. Abletshauser, and C. Sieder et al. A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study J Thromb Haemost 8 2010 1209 1215
35. H. Decousus, V.F. Tapson, J.F. Bergmann, B.H. Chong, J.B. Froehlich, and A.K. Kakkar et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators Chest 139 2011 69 79
36. R.D. Hull, S.M. Schellong, V.F. Tapson, M. Monreal, M.M. Samama, and P. Nicol et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: A randomized trial Ann Intern Med 153 2010 8 18
37. A.T. Cohen, T.E. Spiro, H.R. Buller, L. Haskell, D. Hu, and R. Hull et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients N Engl J Med 368 2013 513 523
38. S.Z. Goldhaber, A. Leizorovicz, A.K. Kakkar, S.K. Haas, G. Merli, and R.M. Knabb et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients N Engl J Med 365 2011 2167 2177
39. M. Sakon, T. Kobayashi, and T. Shimazui Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study Thromb Res 125 2010 e65 e70
40. G. Simonneau, S. Laporte, P. Mismetti, A. Derlon, K. Samii, and C.M. Samama et al. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer J Thromb Haemost 4 2006 1693 1700 (Pubitemid 44144795)
41. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group Br J Surg 84 1997 1099 1103
42. D. Bergqvist, G. Agnelli, A.T. Cohen, A. Eldor, P.E. Nilsson, and A. Le Moigne-Amrani et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer N Engl J Med 346 2002 975 980 (Pubitemid 34983247)
43. G.H. Lyman, A.A. Khorana, N.M. Kuderer, A.Y. Lee, J.I. Arcelus, and E.P. Balaban et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 31 2013 2189 2204
44. A. Kleinjan, A. Aggarwal, A. Van de Geer, C. Faselis, and H.R. Buller et al. A worldwide survey to assess the current approach to the treatment of patients with cancer and venous thromboembolism Thromb Haemost 110 2013 959 965
45. B.A. Hutten, M.H. Prins, M. Gent, J. Ginsberg, J.G. Tijssen, and H.R. Büller Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis J Clin Oncol 18 2000 3078 3083
46. P. Prandoni, A.W. Lensing, A. Piccioli, E. Bernardi, P. Simioni, and B. Girolami et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 100 2002 3484 3488 (Pubitemid 35303914)
47. G. Palareti, C. Legnani, A. Lee, C. Manotti, J. Hirsh, and A. D'Angelo et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy Thromb Haemost 84 2000 805 810
48. S.R. Deitcher, C.M. Kessler, G. Merli, J.R. Rigas, and R.M. Lyons Fareed J; ONCENOX [Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period Clin Appl Thromb Hemost 12 2006 389 396 (Pubitemid 44359237)
49. R.D. Hull, G.F. Pineo, R.F. Brant, A.F. Mah, N. Burke, and R. Dear et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer Am J Med 119 2006 1062 1072 (Pubitemid 44826932)
50. A.Y. Lee, M.N. Levine, R.I. Baker, C. Bowden, A.K. Kakkar, and M. Prins et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N Engl J Med 349 2003 146 153 (Pubitemid 36818784)
51. G. Meyer, Z. Marjanovic, J. Valcke, B. Lorcerie, Y. Gruel, and P. Solal-Celigny et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study Arch Intern Med 162 2002 1729 1735
52. E.A. Akl, N. Labedi, M. Barba, I. Terrenato, F. Sperati, and P. Muti et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer Cochrane Database Syst Rev 6 2011 CD006650
53. A.Y. Lee, R. Bauersachs, M.S. Janas, M.F. Jarner, and P.W. Kamphuisen et al. CATCH: A randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients BMC Cancer 13 2013 284
54. J. Trujillo-Santos, J.A. Nieto, G. Tiberio, A. Piccioli, P. Di Micco, and P. Prandoni et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry Thromb Haemost 100 2008 435 439
55. A. Kakkar, C. Kessler, S.Z. Goldhaber, M. Kovacs, A. Spyropoulos, and M. Huisman et al. Dalteparin sodium for the long-term management of venous thromboembolism in cancer patients The DALTECAN Study. ISTH 2013 abstract AS 12.3
56. M.N. Levine, C. Gu, H.A. Liebman, C.P. Escalante, S. Solymoss, and D. Deitchman et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer J Thromb Haemost 10 2012 807 814
57. S. Schulman, C. Kearon, A. Kakkar, P. Mismetti, S. Schellong, and H. Eriksson et al. RE-COVER study [group. Dabigatran versus warfarin in the Treatment of Acute Venous Thromboembolism N Engl J Med 361 2009 2342 2352
58. H.R. Buller, M.H. Prins, A.W. Lensing, H. Decousus, B.F. Jacobson, and E. Minar et al. Einstein investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 2012 1287 1297
59. R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, H. Decousus, and A.S. Gallus et al. Einstein-PE investigators. Oral rivaroxaban for symptomatic venous thromboembolism N Engl J Med 363 2010 2499 2510
60. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, and M. Johnson et al. Amplify investigators. Oral apixaban for the treatment of acute venous thromboembolism N Engl J Med 369 2013 799 808
61. Hokusai-VTE Investigators, H.R. Büller, H. Décousus, M.A. Grosso, M. Mercuri, S. Middeldorp, and M.H. Prins et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism N Engl J Med 369 2013 1406 1415
62. S. Schulman, H. Eriksson, S.Z. Goldhaber, A. Kakkar, C. Kearon, and S.M. Schellong et al. Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II ASH 2013 abstract 582
63. G.E. Raskob, H.R. Büller, P. Angchaisuksiri, D. Oh, Z. Boda, and R.M. Lyons et al. Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients ASH 2013 abstract 211